This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Jul 21;128(3):318-9.

doi: 10.1182/blood-2016-06-719856.

A new era of immune therapy in multiple myeloma

Yu-Tzu Tai¹, Kenneth C Anderson¹

Affiliations

PMID: 27445408
DOI: 10.1182/blood-2016-06-719856

Free article

Comment

A new era of immune therapy in multiple myeloma

Yu-Tzu Tai et al. Blood. 2016.

Free article

. 2016 Jul 21;128(3):318-9.

doi: 10.1182/blood-2016-06-719856.

Authors

Yu-Tzu Tai¹, Kenneth C Anderson¹

Affiliation

¹ DANA-FARBER CANCER INSTITUTE.

PMID: 27445408
DOI: 10.1182/blood-2016-06-719856

No abstract available

PubMed Disclaimer

Comment on

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK. Krejcik J, et al. Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24. Blood. 2016. PMID: 27222480 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information